CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2013-03-06): Eradicating hepatitis C cuts liver cancer risk: meta-analysis

Epidemiology

Eradicating hepatitis C cuts liver cancer risk: meta-analysis

Last Updated: 2013-03-06 15:25:05 -0400 (Reuters Health)

NEW YORK (Reuters Health) - A sustained virologic response (SVR) to treatment for hepatitis C protects against hepatocellular carcinoma (HCC), a new meta-analysis shows.

Among the implications is that "doctors talk about testing with baby boomers and others at risk for hepatitis C, as early detection and referral to care are critical for hepatitis C patients," Rebecca L. Morgan from the Centers for Disease Control and Prevention, who worked on the analysis, told Reuters Health by email.

Her group's findings were "similar among persons at all stages of liver disease and those with advanced liver disease," she said.

The meta-analysis, she explained, was conducted as part of the evidence review in support of the CDC's expanded HCV testing recommendations for baby boomers released in 2012.

The review, published March 5 in Annals of Internal Medicine, specifically examined reduction in the development of HCC with eradication of HCV. "While several previously published meta-analyses have examined the relationship between response to treatment and development of liver cancer, this review is unique because it takes into account adjusted estimates controlling for other known risk factors of liver cancer," Morgan said.

Pooled analysis of 12 studies (involving 25,497 patients) showed that achieving SVR is associated with a significant reduction in risk for HCC for people at all stages of liver disease (relative risk 0.24; p<0.001). Roughly 1.5% of patients responding to treatment developed HCC, compared with 6.2% of patients who did not respond. As a result, the absolute reduction in risk was 4.6% for patients achieving SVR, the authors say.

Pooled data from six studies and two sub-analyses of 2,649 patients with advanced liver disease found that SVR was associated with a similar reduction in risk for HCC (RR 0.23; p<0.001), they note. Overall, 28.5% of patients achieved SVR, and 4.2% of them developed HCC, compared with 17.8% of nonresponders.

Morgan told Reuters Health that based on previously published studies, "we expected a positive association between a viral cure to hepatitis C treatment and development of liver cancer; however, we did not expect a relative risk reduction of over 75% in the development of liver cancer."

Also, she said, "though not unexpected but more clearly delineated in this comprehensive review, we were able to calculate pooled incidence rates of liver cancer development among persons achieving a viral cure or not achieving a viral cure, and determined that there is over a three-fold baseline risk of developing liver cancer among persons who do not achieve a viral cure."

These findings "should be considered when weighing the benefits and harms of identifying and treating HCV-infected patients," the authors of the report conclude.

SOURCE: http://bit.ly/XUDdCj

Ann Intern Med 2013.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.